MarketCap
Facebook
X
Telegram
Affimed N.V. Total Non Current Liabilities | AFMD
Annual Total Non Current Liabilities Affimed N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.4 M | 12.9 M | 24.6 M | 36.7 M | 38.5 M | 39.2 M | 4.09 M | 3.62 M | 3.1 M | 3.9 M | 90.8 M | 78.2 M | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 90.8 M | 3.1 M | 29.1 M |
Quarterly Total Non Current Liabilities Affimed N.V.
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.79 M | 13.4 M | - | 9.9 M | - | - | 16.1 M | - | 24.6 M | - | 30 M | - | 36.7 M | - | 28.2 M | - | 38.5 M | - | 39.7 M | - | 39.2 M | - | - | - | 4.09 M | - | - | - | 3.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 39.7 M | 3.62 M | 22.4 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 1.24 | 3.33 % | $ 56.7 M |  Israel |
 |
AnaptysBio
ANAB
|
654 K | $ 48.73 | 0.72 % | $ 1.41 B |  USA |
 |
Assembly Biosciences
ASMB
|
18.2 M | $ 22.36 | 4.73 % | $ 251 M | USA |
 |
Adagene
ADAG
|
1.19 M | $ 2.14 | 4.39 % | $ 126 M |  China |
 |
Benitec Biopharma
BNTC
|
213 K | $ 9.47 | 2.05 % | $ 441 M | USA |
 |
Denali Therapeutics
DNLI
|
32.7 M | $ 19.74 | -0.55 % | $ 3.41 B | USA |
 |
Amarin Corporation plc
AMRN
|
17 M | $ 11.68 | -0.64 % | $ 4.85 B |  Irlanda |
 |
ImmuCell Corporation
ICCC
|
11.5 M | $ 10.19 | -0.7 % | $ 92 M | USA |
 |
Editas Medicine
EDIT
|
113 M | $ 2.38 | -4.99 % | $ 211 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
21.9 M | $ 32.84 | 3.38 % | $ 1.9 B | USA |
 |
Cue Biopharma
CUE
|
4.31 M | $ 19.08 | 1.71 % | $ 1.81 B | USA |
 |
Equillium
EQ
|
8.33 M | $ 1.41 | -3.09 % | $ 80.8 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
15.1 M | $ 1.61 | 0.63 % | $ 91.6 M | USA |
 |
Abeona Therapeutics
ABEO
|
30.8 M | $ 2.35 | -4.28 % | $ 124 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 18.38 | 0.55 % | $ 3.09 B | USA |
 |
PainReform Ltd.
PRFX
|
267 K | $ 0.74 | -6.69 % | $ 480 K | Israel |
 |
Atossa Therapeutics
ATOS
|
11.1 K | $ 2.04 | -4.67 % | $ 17.6 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
8.46 K | - | -7.31 % | $ 49 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
490 K | $ 1.01 | -1.46 % | $ 46.8 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
44.4 M | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
439 M | $ 1.6 | 5.3 % | $ 203 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
149 M | $ 34.22 | 2.0 % | $ 1.97 B | USA |
 |
Ardelyx
ARDX
|
246 M | $ 3.14 | 4.15 % | $ 757 M | USA |
 |
Akebia Therapeutics
AKBA
|
181 M | $ 0.57 | 5.2 % | $ 147 M | USA |
 |
Alector
ALEC
|
193 M | $ 2.62 | 3.56 % | $ 270 M | USA |
 |
ALX Oncology Holdings
ALXO
|
5.97 M | $ 1.12 | 0.9 % | $ 60.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.79 B | $ 21.71 | 1.52 % | $ 6.8 B | USA |
|
Phathom Pharmaceuticals
PHAT
|
565 M | $ 6.28 | 15.34 % | $ 458 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
12 M | $ 3.88 | 1.44 % | $ 743 M |  Canada |
 |
Agenus
AGEN
|
264 M | $ 7.24 | 3.06 % | $ 215 M | USA |
 |
AbCellera Biologics
ABCL
|
326 M | $ 12.15 | -2.53 % | $ 3.63 B | Canada |
|
Immatics N.V.
IMTX
|
35.2 M | $ 6.69 | 4.13 % | $ 819 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
5 M | $ 0.77 | -28.31 % | $ 243 K | USA |
 |
Aligos Therapeutics
ALGS
|
13.8 M | $ 2.17 | -15.56 % | $ 21.5 M | USA |
 |
Aclaris Therapeutics
ACRS
|
28.7 M | $ 4.35 | 4.82 % | $ 533 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
198 M | $ 29.93 | 1.94 % | $ 4.54 B | USA |
 |
Cellectar Biosciences
CLRB
|
309 K | $ 1.21 | -0.82 % | $ 3.16 M | USA |
|
Larimar Therapeutics
LRMR
|
6 M | $ 2.74 | 1.67 % | $ 228 M | USA |
 |
Replimune Group
REPL
|
108 M | $ 21.77 | -6.49 % | $ 2.02 B | USA |
 |
Biofrontera AG
BFRA
|
40.7 M | - | -8.24 % | $ 105 M | Germany |
 |
Pharming Group N.V.
PHAR
|
129 M | $ 13.4 | 2.92 % | $ 9.23 B |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
397 K | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
14.3 M | $ 11.21 | 26.38 % | $ 521 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
682 M | $ 28.59 | -1.62 % | $ 1.34 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
38.7 M | - | 1.68 % | $ 4.65 B | China |
 |
Aquestive Therapeutics
AQST
|
146 M | $ 3.59 | 1.85 % | $ 384 M | USA |
 |
Jaguar Health
JAGX
|
10.3 M | $ 0.48 | 10.08 % | $ 1.12 M | USA |
 |
Arvinas
ARVN
|
142 M | $ 6.92 | -0.36 % | $ 491 M | USA |
 |
Cerus Corporation
CERS
|
56.1 M | $ 2.12 | 8.46 % | $ 404 M | USA |